Categories Earnings, Health Care

ESSA Pharma posts narrower loss in Q2

ESSA Pharma Inc. (EPIX) reported a narrower loss in the second quarter of 2019 helped by lower research and development expenses as well as a decline in general and administration expenditures. The company remained on track to enter clinical studies with the metastatic castration-resistant prostate cancer-treating candidate in the first quarter of 2020.

Net loss was $3.4 million or $0.54 per share, narrower than the previous year quarter’s loss of $4.4 million or $0.83 per share. The company experienced an increase in weighted average common shares outstanding.

R&D expenses plunged by 25% year-over-year, primarily related to the company’s continued focus on preclinical research related to its next-generation aniten compounds in the current period.

Image for representation only (Courtesy: Colin Behrens from Pixabay)

Costs in the comparative period included termination costs in relation to ESSA’s conclusion of its phase 1 clinical study of prostate cancer-treating nonsteroidal antiandrogen, EPI-506, in September 2017.

General and administration expenditures fell by 18.2% year-over-year, primarily reflected decreased corporate activity, resulting in decreased professional and regulatory fees.

The company said it is extremely excited about the potential of EPI-7386 after selecting it as a lead clinical candidate for the treatment of metastatic castration-resistant prostate cancer during the first quarter. The company remained on track to enter clinical studies with EPI-7386 in the first quarter of 2020.

Preclinical data showed EPI-7386 is significantly more potent, metabolically stable and more effective than the prior clinical candidate, EPI-506. Also, EPI-7386 has demonstrated a favorable tolerability profile in all animal studies of the compound conducted to date.

Shares of ESSA Pharma ended Thursday’s regular session up 2.54% at $2.63 on the Nasdaq. The stock has fallen over 32% in the past year and over 31% in the past three months.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top